Standard balloon angioplasty versus angioplasty with paclitaxel-eluting balloons for femoropopliteal artery stenosis

Journal of Cardiovascular Surgery

Volumn 53, Issue 4, 2012, Pages 459-463

  Ju, M H ^a   Rodriguez H E ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Angioplasty; Atherosclerosis; Drug eluting stents; Paclitaxel

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CONTRAST MEDIUM; HEPARIN; PACLITAXEL; BIOMATERIAL; CARDIOVASCULAR AGENT;

ANGIOPLASTY; ARTERY INTIMA PROLIFERATION; ARTERY OCCLUSION; DRUG ELUTING STENT; FEMOROPOPLITEAL ARTERY STENOSIS; FOLLOW UP; HUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; REVIEW; ANIMAL; FEMORAL ARTERY; INSTRUMENTATION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POPLITEAL ARTERY; STENOSIS, OCCLUSION AND OBSTRUCTION; TREATMENT OUTCOME;

ANGIOPLASTY, BALLOON; ANIMALS; ARTERIAL OCCLUSIVE DISEASES; CARDIOVASCULAR AGENTS; COATED MATERIALS, BIOCOMPATIBLE; CONSTRICTION, PATHOLOGIC; DRUG-ELUTING STENTS; FEMORAL ARTERY; HUMANS; PACLITAXEL; POPLITEAL ARTERY; TREATMENT OUTCOME;

EID: 84867318840     PISSN: 00219509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. Criqui MH, Denenberg JO, Langer RD, Fronek A. The epidemiology of peripheral arterial disease: importance of identifying the population at risk. Vasc Med 1997;2:221-6. (Pubitemid 27468155)
2. Goodney PP, Beck AW, Nagle J, Welch HG, Zwolak RM. National trends in lower extremity bypass surgery, endovascular interventions, and major amputations. J Vasc Surg 2009;50:54-60.
3. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 2007;45(Suppl S):S5-67.
4. Hunink MG, Wong JB, Donaldson MC, Meyerovitz MF, de Vries J, Harrington DP. Revascularization for femoropopliteal disease. A decision and cost-effectiveness analysis. Jama 1995;274:l65-71.
5. Schillinger M, Sabeti S, Loewe C, Dick P, Amighi J, Mlekusch W et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med 2006;354:1879-88. (Pubitemid 43872689)
6. Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg 2000;31(1 Pt 2):S1-S296.
7. Johnston KW. Femoral and popliteal arteries: reanalysis of results of balloon angioplasty. Radiology 1992;183:767-71.
8. Minar E, Pokrajac B, Maca T, Ahmadi R, Fellner C, Mittlböck M et al. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: results of a prospective randomized study. Circulation 2000;102:2694-9.
9. Lumsden AB, Davies MG, Peden EK. Medical and endovascular management of critical limb ischemia. J Endovasc Ther 2009;16(2 Suppl 2):II31-62.
10. Marx SO, Marks AR. Bench to bedside: the development of rapamycin and its application to stent restenosis. Circulation 2001;104:852-5. (Pubitemid 32778031)
11. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-80. (Pubitemid 34586912)
12. Axel DI, Kunert W, Goggelmann C, Göggelmann C, Oberhoff M, Herdeg C, Küttner A et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 1997;96:636-45. (Pubitemid 27329445)
13. De Luca G, Dirksen MT, Spaulding C, Kelbaek H, Schalij M, Thuesen L et al. Drug-eluting vs bare-metal stents in primary angioplasty: a pooled patient-level meta-analysis of randomized trials. Arch Intern Med 23;172:611-21; discussion 621-612.
14. Duda SH, Bosiers M, Lammer J, Scheinert D, Zeller T, Oliva V et al. Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-term results from the SIROCCO trial. J Endovasc Ther 2006;13:701-10. (Pubitemid 44907633)
15. Dake MD, Ansel GM, Jaff MR, Ohki T, Saxon RR, Smouse HB et al. Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results. Circ Cardiovasc Interv 2011;4:495-504.
16. Scheinert D, Scheinert S, Sax J, Piorkowski C, Bräunlich S, Ulrich M et al. Prevalence and clinical impact of stent fractures after femoropopliteal stenting. J Am Coll Cardiol 2005;45:312-5. (Pubitemid 40094743)
17. Gray WA, Granada JF. Drug-coated balloons for the prevention of vascular restenosis. Circulation 2010;121:2672-80.
18. Diehm NA, Hoppe H, Do DD. Drug eluting balloons. Tech Vasc Interv Radiol 2010;13:59-63.
19. Scheller B, Speck U, Abramjuk C, Bernhardt U, Bohm M, Nickenig G. Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis. Circulation 2004;110:810-4. (Pubitemid 39096008)
20. Tepe G, Zeller T, Albrecht T, Heller S, Schwarzwälder U, Beregi JP et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med 2008;358:689-99. (Pubitemid 351240748)
21. Werk M, Langner S, Reinkensmeier B, Boettcher HF, Tepe G, Dietz U et al. Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation 2008;118:1358-65.
22. Werk M, Albercht R, Meyer DR, Stiepani H, Schnorr B, Lopez- Hänninenet E. The Pacifier Trial. A Randomized Multicenter Trial Evaluating Prevention of Restenosis with Paclitaxel-Coated PTA Balloon Catheters in Stenosis or Occlusion of Femoropopliteal Arteries: First Report. J Am Coll Cardiol 2011;58(20S1):B79-B79.
23. Cioppa A, Stabile E, Popusoi G, Salemme L, Cota L, Pucciarelli A et al. Combined treatment of heavy calcified femoro-popliteal lesions using directional atherectomy and a paclitaxel coated balloon: One-year single centre clinical results. Cardiovasc Revasc Med 2012 [Epub ahead of print].